Heart Outcomes Prevention Evaluation
HOPE‑3 was a multinational randomised controlled study to evaluate the effects of the ‘polypill' (a combined cholesterol and blood pressure lowering medication), in 12,500 study participants who were without vascular disease at study entry. Study participants were followed for between 4-8 years, with the study completion in October 2015. CCRE CTC recruited study participants as well as coordinating and monitoring the other sites in Australia; The George Institute for International Health in Dubbo and in Sydney; and Canberra Hospital. Three papers examining the results of the HOPE-3 study were published in the New England Journal of Medicine in April 2016.
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease: “The combination of rosuvastatin, candesartan, and hydrochlorothiazide was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease.”
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease: “Therapy with candesartan plus hydrochlorothiazide was not associated with a lower rate of major cardiovascular events than placebo among persons at intermediate risk who did not have cardiovascular disease.”
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease: “Treatment with rosuvastatin resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease.”
After conclusion of the active HOPE-3 phase, most study sites worldwide have agreed to passive follow-up of the study participants which concludes at the end of 2018 with a final report due early 2019. This data will provide information relating to the long-term effects of the blood pressure and lipid lowering and see if it persists (or is enhanced) in a primary prevention population.
This study is conducted by Population Health Research Institute, Canada, with funding provided by the Canadian Institutes of Health Research and AstraZeneca